Search

Your search keyword '"Luppi, Fabrizio"' showing total 580 results
Start Over Author "Luppi, Fabrizio"
580 results on '"Luppi, Fabrizio"'

3. Two-year cardio-pulmonary follow-up after severe COVID-19: a prospective study

Author

Faverio, Paola, Paciocco, Giuseppe, Tassistro, Elena, Rebora, Paola, Rossi, Emanuela, Monzani, Anna, Tundo, Marta, Milano, Chiara, Messa, Martina, Marocchi, Raffaele, Pesci, Alberto, Foti, Giuseppe, Squillace, Nicola, Cogliandro, Viola, Lettino, Maddalena, Strepparava, Maria Grazia, Bellelli, Giuseppe, Ferrarese, Carlo, Valsecchi, Maria Grazia, Bonfanti, Paolo, and Luppi, Fabrizio

Published
2024
Full Text
View/download PDF

14. One-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study

Author

Faverio, Paola, Luppi, Fabrizio, Rebora, Paola, D’Andrea, Gabriele, Stainer, Anna, Busnelli, Sara, Catalano, Martina, Modafferi, Giuseppe, Franco, Giovanni, Monzani, Anna, Galimberti, Stefania, Scarpazza, Paolo, Oggionni, Elisa, Betti, Monia, Oggionni, Tiberio, De Giacomi, Federica, Bini, Francesco, Bodini, Bruno Dino, Parati, Mara, Bilucaglia, Luca, Ceruti, Paolo, Modina, Denise, Harari, Sergio, Caminati, Antonella, Intotero, Marcello, Sergio, Pietro, Monzillo, Giuseppe, Leati, Giovanni, Borghesi, Andrea, Zompatori, Maurizio, Corso, Rocco, Valsecchi, Maria Grazia, Bellani, Giacomo, Foti, Giuseppe, and Pesci, Alberto

Published
2022
Full Text
View/download PDF

15. Sarcopenia in idiopathic pulmonary fibrosis: a prospective study exploring prevalence, associated factors and diagnostic approach

Author

Faverio, Paola, Fumagalli, Alessia, Conti, Sara, Madotto, Fabiana, Bini, Francesco, Harari, Sergio, Mondoni, Michele, Oggionni, Tiberio, Barisione, Emanuela, Ceruti, Paolo, Papetti, Maria Chiara, Bodini, Bruno Dino, Caminati, Antonella, Valentino, Angela, Centanni, Stefano, Lanzi, Paola, Della Zoppa, Matteo, Crotti, Silvia, Grosso, Marco, Sukkar, Samir Giuseppe, Modina, Denise, Andreoli, Marco, Nicali, Roberta, Suigo, Giulia, Busnelli, Sara, Paciocco, Giuseppe, Lettieri, Sara, Mantovani, Lorenzo Giovanni, Cesana, Giancarlo, Pesci, Alberto, and Luppi, Fabrizio

Published
2022
Full Text
View/download PDF

16. Therapeutic Management of Bronchiectasis in Children and Adolescents: A Concise Narrative Review.

Author

Faverio, Paola, Franco, Giovanni, Landoni, Valentina, Nadalin, Marta, Negri, Davide, Tagliabue, Alessandro, Acone, Federica, Cattaneo, Francesca, Cipolla, Filippo, Vimercati, Chiara, Aliberti, Stefano, Biondi, Andrea, and Luppi, Fabrizio

Subjects
LUNG transplantation, IMMUNIZATION of children, ANTIBIOTIC prophylaxis, INFLUENZA vaccines, LUNG surgery
Abstract

Introduction: Bronchiectasis, characterized by airway dilation, mucus hypersecretion, and recurrent exacerbations, is increasingly recognized in children and adolescents. Recent guidelines from the European Respiratory Society (ERS) and Thoracic Society of Australia and New Zealand (TSANZ) emphasize early diagnosis and optimized management. This review explores therapeutic strategies for pediatric bronchiectasis. Materials and methods: Our review involved a comprehensive search of English-language literature in the PubMed and EMBASE databases until December 2023, focusing on observational studies, interventions, reviews, and guidelines in pediatric bronchiectasis. Results: Management strategies encompass airway clearance techniques, mucoactive agents, pulmonary rehabilitation, bronchodilators and inhaled corticosteroids tailored to individual needs and age-appropriate techniques. Antibiotics play key roles in preventing exacerbations, eradicating pathogens, and managing acute exacerbations, which are guided by culture sensitivities and symptoms. Long-term antibiotic prophylaxis, particularly macrolides, aims to reduce exacerbations, although concerns about antibiotic resistance persist. Vaccinations, including pneumococcal and influenza vaccines, are crucial for preventing infections and complications. Surgery and lung transplantation are reserved to severe, refractory cases after failure of medical therapies. Conclusions: The optimal management of pediatric bronchiectasis requires a multidisciplinary approach, including physiotherapy, pharmacotherapy, and vaccinations, tailored to individual needs and guided by evidence-based guidelines. Further research is needed to refine diagnostic and therapeutic strategies and improve outcomes for affected children and adolescents. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Diagnostic delay in bronchiectasis: an Italian perspective

Author

Chessari, Carlo, primary, Simonetta, Edoardo, additional, Amati, Francesco, additional, Nigro, Mattia, additional, Stainer, Anna, additional, Sotgiu, Giovanni, additional, Puci, Mariangela, additional, Gramegna, Andrea, additional, Blasi, Francesco, additional, Morlacchi, Letizia Corinna, additional, Buscemi, Agata Alba Maria Domenica, additional, Conio, Valentina, additional, Sanci, Vincenzo, additional, Corsico, Angelo G., additional, Faverio, Paola, additional, Michalak, Weronika, additional, Luppi, Fabrizio, additional, Crimi, Claudia, additional, Vancheri, Carlo, additional, Campisi, Raffaele, additional, Vulpi, Maria Rosaria, additional, Carpagnano, Giovanna Elisiana, additional, Cicchetti, Marianna, additional, Sekretna, Kseniia, additional, Scichilone, Nicola, additional, Battaglia, Salvatore, additional, and Aliberti, Stefano, additional

Published
2024
Full Text
View/download PDF

20. Rheumatoid arthritis extra-articular lung disease: new insights on pathogenesis and experimental drugs

Author

Sebastiani, Marco, Manfredi, Andreina, Croci, Stefania, Faverio, Paola, Cassone, Giulia, Vacchi, Caterina, Salvarani, Carlo, and Luppi, Fabrizio

Abstract

ABSTRACTIntroductionPulmonary involvement is one of the most common extra-articular manifestations of rheumatoid arthritis (RA), a systemic inflammatory disease characterized by joint swelling and tenderness. All lung compartments can be interested in the course of RA, including parenchyma, airways, and, more rarely, pleura and vasculature.Areas coveredThe aim of this paper is to review the main RA lung manifestations, focusing on pathogenesis, clinical and therapeutic issues of RA-related interstitial lung disease (ILD). Despite an increasing number of studies in the last years, pathogenesis of RA-ILD remains largely debated and the treatment of RA patients with lung involvement is still challenging in these patients.Expert opinionManagement of RA-ILD is largely based on expert-opinion. Due to the broad clinical manifestations, including both joints and pulmonary involvement, multidisciplinary discussion, including rheumatologist and pulmonologist, is essential, not only for diagnosis, but also to evaluate the best therapeutic approach and follow-up. In fact, the coexistence of different lung manifestations may influence the treatment response and safety. The identification of biomarkers and risk-factors for an early identification of RA patients at risk of developing ILD remains a need that still needs to be fulfilled, and that will require further investigation in the next years.

Published
2024
Full Text
View/download PDF

21. Two-year cardio-pulmonary follow-up after severe COVID-19: a prospective study

Author

Faverio, P, Paciocco, G, Tassistro, E, Rebora, P, Rossi, E, Monzani, A, Tundo, M, Milano, C, Messa, M, Marocchi, R, Pesci, A, Foti, G, Squillace, N, Cogliandro, V, Lettino, M, Strepparava, M, Bellelli, G, Ferrarese, C, Valsecchi, M, Bonfanti, P, Luppi, F, Faverio, Paola, Paciocco, Giuseppe, Tassistro, Elena, Rebora, Paola, Rossi, Emanuela, Monzani, Anna, Tundo, Marta, Milano, Chiara, Messa, Martina, Marocchi, Raffaele, Pesci, Alberto, Foti, Giuseppe, Squillace, Nicola, Cogliandro, Viola, Lettino, Maddalena, Strepparava, Maria Grazia, Bellelli, Giuseppe, Ferrarese, Carlo, Valsecchi, Maria Grazia, Bonfanti, Paolo, Luppi, Fabrizio, Faverio, P, Paciocco, G, Tassistro, E, Rebora, P, Rossi, E, Monzani, A, Tundo, M, Milano, C, Messa, M, Marocchi, R, Pesci, A, Foti, G, Squillace, N, Cogliandro, V, Lettino, M, Strepparava, M, Bellelli, G, Ferrarese, C, Valsecchi, M, Bonfanti, P, Luppi, F, Faverio, Paola, Paciocco, Giuseppe, Tassistro, Elena, Rebora, Paola, Rossi, Emanuela, Monzani, Anna, Tundo, Marta, Milano, Chiara, Messa, Martina, Marocchi, Raffaele, Pesci, Alberto, Foti, Giuseppe, Squillace, Nicola, Cogliandro, Viola, Lettino, Maddalena, Strepparava, Maria Grazia, Bellelli, Giuseppe, Ferrarese, Carlo, Valsecchi, Maria Grazia, Bonfanti, Paolo, and Luppi, Fabrizio

Abstract

Short- and medium-term cardio-pulmonary sequelae after COVID-19 have been extensively studied. However, studies with longer follow-ups are required. This study aims to identify and characterise cardio-pulmonary sequelae, in patients hospitalised for SARS-CoV-2 pneumonia, at 24 months follow-up. This is a prospective, observational cohort study conducted on consecutive patients hospitalised for COVID-19 and acute respiratory failure. Patients were followed up at 24 months with complete pulmonary function tests (PFTs), 6-min walking test and a dyspnoea score (Modified Medical Research Council scale). A subgroup of patients with at least one clinical or functional sign suggestive of increased pulmonary pressures also underwent transthoracic echocardiography (TTE) to evaluate the presence of direct or indirect signs of pulmonary hypertension (PH). Ninety consecutive patients (74% men, median age 59.1 years) were enrolled in the study. In regard to PFTs, carbon monoxide diffusion capacity (DLCO) impairment was observed in 23 cases (26%), in all cases of mild entity. When considering the dyspnoea, 30 (34%) patients showed some degree of breathlessness. Forty patients underwent TTE. No patients had overt PH or chronic thromboembolic PH. However, all patients showed a hyperdynamic state of the right ventricle, and 8 (20%) patients had a decreased acceleration time on pulmonary valve, signs of increased pulmonary vasculature resistances and afterload elevation. At 24-month follow-up after severe COVID-19, DLCO and TTE prove to be the most sensitive tool to detect cardio-pulmonary sequelae. Dyspnoea is still present in about one-third of patients and requires a multidisciplinary approach.

Published
2024

22. Cardiovascular Structural and Functional Parameters in Idiopathic Pulmonary Fibrosis at Disease Diagnosis

Author

Faverio, P, Maloberti, A, Rebora, P, Intravaia, R, Tognola, C, Toscani, G, Amato, A, Leoni, V, Franco, G, Vitarelli, F, Spiti, S, Luppi, F, Valsecchi, M, Pesci, A, Giannattasio, C, Faverio, Paola, Maloberti, Alessandro, Rebora, Paola, Intravaia, Rita Cristina Myriam, Tognola, Chiara, Toscani, Giorgio, Amato, Anna, Leoni, Valerio, Franco, Giovanni, Vitarelli, Federica, Spiti, Simona, Luppi, Fabrizio, Valsecchi, Maria Grazia, Pesci, Alberto, Giannattasio, Cristina, Faverio, P, Maloberti, A, Rebora, P, Intravaia, R, Tognola, C, Toscani, G, Amato, A, Leoni, V, Franco, G, Vitarelli, F, Spiti, S, Luppi, F, Valsecchi, M, Pesci, A, Giannattasio, C, Faverio, Paola, Maloberti, Alessandro, Rebora, Paola, Intravaia, Rita Cristina Myriam, Tognola, Chiara, Toscani, Giorgio, Amato, Anna, Leoni, Valerio, Franco, Giovanni, Vitarelli, Federica, Spiti, Simona, Luppi, Fabrizio, Valsecchi, Maria Grazia, Pesci, Alberto, and Giannattasio, Cristina

Abstract

Introduction: Prevalence of cardiac and vascular fibrosis in patients with Idiopathic Pulmonary Fibrosis (IPF) has not been extensively evaluated. Aim: In this study, we aimed to evaluate the heart and vessels functional and structural properties in patients with IPF compared to healthy controls. An exploratory analysis regarding disease severity in IPF patients has been done. Methods: We enrolled 50 patients with IPF (at disease diagnosis before antifibrotic therapy initiation) and 50 controls matched for age and gender. Heart was evaluated through echocardiography and plasmatic NT-pro-brain natriuretic peptide that, together with patients' symptoms, allow to define the presence of Heart Failure (HF) and diastolic dysfunction. Vessels were evaluated through Flow Mediated Dilation (FMD - endothelial function) and Pulse Wave Velocity (PWV-arterial stiffness) RESULTS: Patients with IPF had a prevalence of diastolic disfunction of 83.8%, HF of 37.8% and vascular fibrosis of 76.6%. No statistically significant difference was observed in comparison to the control group who showed prevalence of diastolic disfunction, HF and vascular fibrosis of 67.3%, 24.5% and 84.8%, respectively. Disease severity seems not to affect PWV, FMD, diastolic dysfunction and HF. Conclusions: Patients with IPF early in the disease course do not present a significant CV fibrotic involvement when compared with age- and sex-matched controls. Bigger and adequately powered studies are needed to confirm our preliminary data and longitudinal studies are required in order to understand the time of appearance and progression rate of heart and vascular involvement in IPF subjects.

Published
2024

25. The Role of Serum IgG Precipitins against Six Typical Organic Antigens Involved in Hypersensitivity Pneumonitis: A 10-Year Retrospective Study of a Referral Interstitial Lung Disease Centre.

Author

Intra, Jari, Biffi, Alice, Basta, Francesca, Delfini, Cristina, Novati, Nicoletta, Zucchetti, Elisa, Luppi, Fabrizio, and Casati, Marco

Subjects
INTERSTITIAL lung diseases, HYPERSENSITIVITY pneumonitis, IMMUNOGLOBULIN G, ANTIGENS, ALTERNARIA alternata, PENICILLIUM chrysogenum
Abstract

Hypersensitivity pneumonitis (HP) represents the third common interstitial lung disease caused by an exaggerated immune response following the inhalation of organic and/or chemical environmental antigens. The aim of this study was to determine the cut-off values of specific IgG antibodies (named precipitins) and their association with clinical data in the diagnosis of HP. In this 10-year retrospective study, the IgG concentrations against six antigens, Penicillium chrysogenum/notatum, Aspergillus fumigatus, Alternaria alternata, Aspergillus niger, Micropolyspora faeni, and pigeon droppings, were retrieved. The controlled group was made of 1516 healthy subjects without diagnosis of lung pathologies, while the case group consisted of 54 individuals affected by HP. Considering all six IgG antibodies together and the 97.5% percentiles determined in the control group, 30 of 54 subjects (56%) had one or more positive precipitins. In these patients, the major frequencies found were IgG antibodies against pigeon droppings, followed by Penicillium chrysogenum/notatum and Aspergillus niger. Although the sensitivity of serum precipitins depends on the population enrolled and the method used, the cut-off values determined in this study can be a valuable tool for clinicians in the diagnosis of HP, in eliminating the antigens responsible from the environment, and in establishing more specific IgG panels. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Healthcare costs and resources utilization in children with difficult‐to‐control asthma treated with biologic therapies: A population‐based cohort study

Author

Monzio Compagnoni, Matteo, primary, Conflitti, Claudia, additional, Capuano, Veronica, additional, Bonaiti, Giulia, additional, Franchi, Matteo, additional, Vimercati, Chiara, additional, Biondi, Andrea, additional, Luppi, Fabrizio, additional, Corrao, Giovanni, additional, and Faverio, Paola, additional

Published
2023
Full Text
View/download PDF

33. Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project

Author

Cazzaniga, Marina Elena, primary, Ciaccio, Antonio, additional, Danesi, Romano, additional, Duhoux, Francois P., additional, Girmenia, Corrado, additional, Zaman, Kalhil, additional, Lindman, Henrik, additional, Luppi, Fabrizio, additional, Mavroudis, Dimitrios, additional, Paris, Ida, additional, Olubukola, Ayodele, additional, Samreen, Ahmed, additional, Schem, Christian, additional, Singer, Christian, additional, and Snegovoy, Anton, additional

Published
2023
Full Text
View/download PDF

36. ROX index on 3rd day as a best predictor of treatment failure in severe COVID-19 patients

Author

Novelli, Luca, primary, Centanni, Stefano, additional, Luppi, Fabrizio, additional, Aliberti, Stefano, additional, Rogliani, Paola, additional, Micheletto, Claudio, additional, Contoli, Marco, additional, Sanduzzi Zamparelli, Alessandro, additional, Raimondi, Federico, additional, Pappacena, Simone, additional, Malandrino, Luca, additional, Lorini, Giorgio, additional, Carioli, Greta, additional, and Di Marco, Fabiano, additional

Published
2023
Full Text
View/download PDF

37. OSA phatophysiological traits in Milan and Monza-Brianza

Author

Perger, Elisa, primary, Monzani, Anna, additional, Meriggi, Paolo, additional, V. Matias, Margarida, additional, Garzillo, Laura, additional, Tundo, Marta, additional, Foresi, Antonio, additional, Parati, Gianfranco, additional, Faverio, Paola, additional, Luppi, Fabrizio, additional, and Lombardi, Carolina, additional

Published
2023
Full Text
View/download PDF

40. Short-term evolution of nutritional status in patients with idiopathic pulmonary fibrosis

Author

Franco, Giovanni, primary, Faverio, Paola, additional, Fumagalli, Alessia, additional, Conti, Sara, additional, Madotto, Fabiana, additional, Bini, Francesco, additional, Harari, Sergio, additional, Mondoni, Michele, additional, Oggioni, Tiberio, additional, Barisone, Emanuela, additional, Ceruti, Paolo, additional, Papetti, Maria Chiara, additional, Bodini, Bruno Dino, additional, Caminati, Antonella, additional, Valentino, Angela, additional, Centanni, Stefano, additional, Lanzi, Paola, additional, Della Zoppa, Matteo, additional, Crotti, Silvia, additional, Grosso, Marco, additional, Sukkar, Samir Giuseppe, additional, Modina, Denise, additional, Andreoli, Marco, additional, Nicali, Roberta, additional, Suigo, Giulia, additional, Busnelli, Sara, additional, Paciocco, Giuseppe, additional, Lettieri, Sara, additional, Mantovani, Lorenzo Giovanni, additional, Cesana, Giancarlo, additional, Pesci, Alberto, additional, and Luppi, Fabrizio, additional

Published
2023
Full Text
View/download PDF

41. Covid-19 infection and chronic thromboembolic pulmonary disease: screening role of transthoracic echocardiography 2 years after hospitalization for interstitial pneumonia

Author

Tundo, Marta, primary, Lombi, Andrea, additional, Milano, Chiara, additional, Messa, Martina, additional, Volpiano, Lorenzo, additional, Ripamonti, Riccardo, additional, Alfieri, Paola, additional, Pittalis, Giulia, additional, Luppi, Fabrizio, additional, Faverio, Paola, additional, and Paciocco, Giuseppe, additional

Published
2023
Full Text
View/download PDF

45. Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?

Author

Albera, Carlo, Antoniou, Katerina M., Altinisik, Goksel, Bendstrup, Elisabeth, Bondue, Benjamin, Borie, Raphael, Brown, Kevin K., Camus, Philippe, Castillo, Diego, Collard, Harold R., Cottin, Vincent, Crimi, Nunzio, Ferrara, Giovanni, Fischer, Aryeh, Gauldie, Jack, Geiser, Thomas, Guenther, Andreas, Hambly, Nathan, Hansell, David M., Harari, Sergio, Jones, Mark G., Keane, Michael, Ley, Brett, Maher, Toby M., Molina-Molina, Maria, Palmucci, Stefano, Poletti, Venerino, Prasse, Antje, Rottoli, Paola, Spagnolo, Paolo, Sterclova, Martina, Torrisi, Sebastiano, Tsitoura, Eliza, Vasakova, Martina, Walsh, Simon L., Wijsenbeek, Marlies S., Wuyts, Wim A., Johannson, Kerri A, Strâmbu, Irina, Ravaglia, Claudia, Grutters, Jan C, Valenzuela, Claudia, Mogulkoc, Nesrin, Luppi, Fabrizio, Richeldi, Luca, Wells, Athol U, Vancheri, Carlo, and Kreuter, Michael

Published
2017
Full Text
View/download PDF

48. Short-term Evolution of Nutritional Status in Patients with Idiopathic Pulmonary Fibrosis

Author

Faverio, Paola, primary, Fumagalli, Alessia, additional, Conti, Sara, additional, Madotto, Fabiana, additional, Bini, Francesco, additional, Harari, Sergio, additional, Mondoni, Michele, additional, Oggionni, Tiberio, additional, Barisione, Emanuela, additional, Ceruti, Paolo, additional, Papetti, Maria Chiara, additional, Bodini, Bruno Dino, additional, Caminati, Antonella, additional, Valentino, Angela, additional, Centanni, Stefano, additional, Lanzi, Paola, additional, Della Zoppa, Matteo, additional, Crotti, Silvia, additional, Grosso, Marco, additional, Sukkar, Samir Giuseppe, additional, Modina, Denise, additional, Andreoli, Marco, additional, Nicali, Roberta, additional, Suigo, Giulia, additional, Busnelli, Sara, additional, Paciocco, Giuseppe, additional, Lettieri, Sara, additional, Mantovani, Lorenzo Giovanni, additional, Cesana, Giancarlo, additional, Pesci, Alberto, additional, and Luppi, Fabrizio, additional

Published
2023
Full Text
View/download PDF

50. Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR plus ), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients : a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project

Author

Cazzaniga, Marina Elena, Ciaccio, Antonio, Danesi, Romano, Duhoux, Francois P., Girmenia, Corrado, Zaman, Kalhil, Lindman, Henrik, Luppi, Fabrizio, Mavroudis, Dimitrios, Paris, Ida, Olubukola, Ayodele, Samreen, Ahmed, Schem, Christian, Singer, Christian, Snegovoy, Anton, Cazzaniga, Marina Elena, Ciaccio, Antonio, Danesi, Romano, Duhoux, Francois P., Girmenia, Corrado, Zaman, Kalhil, Lindman, Henrik, Luppi, Fabrizio, Mavroudis, Dimitrios, Paris, Ida, Olubukola, Ayodele, Samreen, Ahmed, Schem, Christian, Singer, Christian, and Snegovoy, Anton

Abstract

The personalization of therapies in breast cancer has favoured the introduction of new molecular-targeted therapies into clinical practice. Among them, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have acquired increasing importance, with the approval in recent years of palbociclib, ribociclib, and abemaciclib in combination with endocrine therapy. Currently, no guidelines are available to monitor and manage potential long-term toxicities associated with the use of these drugs. A multidisciplinary panel of European oncologists, was supported by a pharmacologist, a hematologist, a hepatologist and a pulmonologist to discuss the management of long-term toxicities, based on the literature review and their clinical experience. The panel provided detailed roadmaps to manage long-term toxicities associated with the use of CDK4/6 inhibitors in clinical practice. Knowing the frequency and characteristics of the toxicity profile associated with each CDK4/6 inhibitor is important in the decision-making process to match the right drug to the right patient.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results